ALKERMES | ALKS - Operating Profit


ALKERMES reported $-65.93M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
AbbVie USD 6.72B 1.99B Jun/2026
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
ALKERMES USD -65.93M 17.65M Jun/2026
Amgen USD 4.61B 777M Jun/2026
Biogen USD -243.8M 758.1M Jun/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
J&J USD 7.48B 860M Jun/2026
Malin Corporation EUR -1.1M 400K Dec/2024
Merck USD 840M 2.72B Jun/2026
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
Otsuka Holdings JPY 140.41B 22.2B Jun/2026
Ovoca Bio EUR -173K 990K Dec/2025
Pfizer USD 667M 4.32B Jun/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026